Is American Express Stock a Buy, Sell, or Hold With Shares Trading 20% Below Their 52-Week High?
Source: The Motley Fool
American Express shares trade near $310, roughly 20% below their December 2025 all-time high of $384.79 and down 16.3% year-to-date, following a 25% gain in 2025. Q2 revenue rose 10% year over year and earnings increased 11%, but expense growth of 12%—driven by marketing and technology investment—has slowed profit growth. The company raised its full-year revenue growth outlook to 10% but maintained earnings guidance, while higher inflation, gas prices and a Fed rate increase create uncertainty around consumer spending and credit performance. Its P/E has declined to 18 from 25 at year-end, but the article recommends holding pending Q3 earnings and greater economic clarity.
Analysis
AXP’s key debate is no longer top-line durability but the incremental cost required to preserve premium-card spend and customer acquisition. If expense growth continues to outpace revenue through Q3, operating leverage reverses and consensus EPS estimates—rather than the current headline multiple—remain vulnerable. AXP’s affluent skew provides better credit resilience than DFS or COF, but it also has disproportionately high exposure to discretionary travel-and-entertainment spend, where a fuel/inflation shock can pressure billed-business growth before delinquencies visibly deteriorate.
Higher rates are not unambiguously positive: incremental card-loan yield is beneficial, but funding costs, charge-offs and reserve needs can offset it with a lag. The near-term stock reaction should hinge on Q3 evidence that marketing dollars are generating durable spend per new account rather than simply defending share against Chase Sapphire and Capital One Venture. Over 6-18 months, sustained investment may be strategically correct, but it lowers the probability of returning to the prior premium valuation until expense-to-revenue leverage normalizes.
Consensus may be too focused on the pullback from peak and insufficiently focused on whether the earnings base has reset. AXP is not a clean cyclical value long if management must choose between growth investment and margin delivery; a lower P/E alone does not create upside without stable forward EPS. The more attractive expression is relative: AXP should outperform lower-credit-quality issuers in a mild slowdown, but underperform Visa and Mastercard if consumer stress is avoided and investors reward asset-light payment volume growth.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.22
Ticker Sentiment
Key Decisions for Investors
- Remain neutral AXP into Q3; initiate a long only if billed-business growth holds near double digits while expense growth decelerates below revenue growth. A guidance cut or another quarter of negative operating leverage falsifies the entry thesis.
- Use a 1-3 month pair trade: long V / short AXP if the base case is resilient consumption but persistent acquisition and technology spending. V offers cleaner payment-volume exposure with materially less credit and funding-cost sensitivity.
- For a mild-recession hedge, pair long AXP / short COF or DFS over 3-6 months, sized modestly. AXP’s premium customer base should produce lower loss volatility; exit if AXP’s net write-off or reserve trends converge toward mass-market issuer deterioration.
- Monitor Q3 marketing efficiency: new-account growth, spending per acquired account, card-loan growth, net interest yield, and provision growth. If spending per new account weakens while marketing remains elevated, avoid averaging down despite further multiple compression.
More News
- Here are the 3 big things we're watching in the stock market this week
- Nvidia CEO Jensen Huang emerges as Trump's top ally in AI safety debate
- Why the White House's Push to Control Bond Markets Is Destined to Disappoint Investors
- Citi CEO Says Companies Scrambling to Launch AI Cyber Defenses
- Neocloud Boom: Comparing Nebius, CoreWeave, & IREN
- Palantir Nearly Doubled Its Revenue. Its Stock Stood Still. Is It Time to Buy the Stock?